Research reportPyrroloquinoline quinone prevents MK-801-induced stereotypical behavior and cognitive deficits in mice

- PQQ reduced the hyperactivity and circular movements among MK-801-treated mice.
- PQQ increased frequent and periods of social interaction in MK-801-induced mice.
- PQQ prevented the MK-801-induced increase in stereotypical, ataxia, and weight loss.
- PQQ blocks the learning and memory deficits that result from MK-801 treatment.
- PQQ may be considered as a novel class of atypical antipsychotic agents.

Pyrroloquinoline quinone (PQQ), an essential nutrient, antioxidant, redox modulator, and nerve growth factor, prevents cognitive deficits associated with oxidative stress-induced neurodegeneration. Previous molecular imaging studies also demonstrate that PQQ binds to N-methyl d-aspartate (NMDA) receptors. In this study, we investigated the effects of PQQ on stereotypical behaviors and cognitive deficits induced by MK-801, a non-competitive NMDA antagonist used to model schizophrenia. Mice were given repeated injections of MK-801 (0.5 mg/kg/d) and PQQ (0.2, 2.0, or 20 μg/kg/d) for 60 days. Behavior was evaluated using a variety of motor, social, and cognitive tests. We found that PQQ administration significantly attenuated MK-801-induced increases in stereotypical behavior and ataxia, suggesting a protective role of PQQ against MK-801-induced neuronal dysfunction and psychiatric disorders. Future studies are necessary to elucidate the underlying mechanisms of PQQ.